Regeneron Pharma (REGN) Could Be Seeing 'Peak Enthusiasm' for COVID Opportunity - Baird
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated a Neutral rating and $600.00 price target on Regeneron Pharma (NASDAQ: REGN), saying while they ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
